Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
This study is seeking participants who meet the following key eligibility criteria:
Diagnosis of advanced/metastatic solid tumor including primary brain tumor.
Qualifying BRAF alteration (V600 or non-V600 Class II/Class III BRAF alteration), in tumor tissue and/or blood (ie circulating tumor deoxyribonucleic acid \[DNA\], or ctDNA).
Disease progressed during/following last prior treatment and no satisfactory alternative treatment options (Part 1, Part 2 (doublet), and Part 3 (cohorts 2, 3, 6, 7)).
Tumor specific cohorts (melanoma, colorectal cancer) must have received specific prior approved therapies
Part 3 (Cohort 4) (BRAF V600E CRC): Minimum of 2 cycles of prior 5-FU based chemotherapy required. No prior BRAF inhibitor/EGFR inhibitor allowed. Participants with MSI-H/dMMR mCRC should receive prior immune checkpoint inhibitor therapy.
Part 3 (Cohort 5) (BRAF V600E CRC): No more than 2 cycles of prior 5-FU based chemotherapy allowed. No prior BRAF inhibitor/EGFR inhibitors allowed. Participants with MSI-H/dMMR mCRC should receive prior immune checkpoint inhibitor therapy.
You may not be if
Brain metastasis larger than 4 cm
Systemic anti-cancer therapy or small molecule therapeutics ongoing at the start of study treatment.
History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO; history of retinal degenerative disease.
Concurrent neuromuscular disorder associated with elevated creatine kinase (CK).
